AVB-114治疗持续性克罗恩病肛瘘的随机对照试验
STOMP2多中心随机试验评估植入式自体细胞疗法AVB-114对比标准治疗对持续性克罗恩病肛周瘘的疗效。
要点
- AVB-114组36周联合缓解率45.8%,标准治疗组8.3%,差异显著
- AVB-114组至36周无严重治疗中出现的不良事件
- 联合缓解定义包括外口闭合、无液体引流及MRI无>2cm集合
核心结论
- AVB-114治疗持续性克罗恩病肛周瘘的36周联合缓解率显著高于标准治疗,且耐受性良好。
研究设计与样本
- 所有入组患者先接受手术瘘管优化和脂肪组织活检采集(用于制造AVB-114),再随机分组;标准治疗组接受重复瘘管优化包括挂线更换。
主要发现
- 第36周联合缓解率:标准治疗组8.3%,AVB-114组45.8%(差异38%,95%CI 11%-60%,P=0.0078)。
- 第36周MRI显示无患者存在>2cm集合;放射学改善(MAGNIFI-CD评分较基线下降≥50%)标准治疗组1例、AVB-114组3例。
- 放射学愈合(瘘管T2加权高信号完全消退)标准治疗组2例、AVB-114组5例。
- 至第36周治疗中出现的不良事件:标准治疗组40例次,AVB-114组56例次;AVB-114组无严重治疗中出现的不良事件。
关键数值与推荐
- 主要终点为第36周联合瘘管缓解,定义为外口闭合、轻柔指压无液体引流、MRI至少2/3维度无>2cm集合。
- 入组标准:单个肛周瘘管,且既往治疗失败或对生物制剂/传统CD治疗记录有不耐受。
临床怎么用
- 对于持续性克罗恩病肛周瘘且既往治疗失败或不耐受的患者,AVB-114可能提供一种有效的治疗选择。
- 治疗前需进行手术瘘管优化和脂肪组织活检以制造AVB-114。
局限性
- 样本量较小(每组24例),随访至36周,长期疗效和安全性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Advanced therapies infrequently achieve complete fistula closure in patients with Crohn's disease (CD). The primary objective of the STOMP2 clinical trial was to determine whether the implantable autologous cell therapy AVB-114 is effective in inducing remission of persistent Crohn's perianal fistulas versus standard of care. METHODS: Eligible patients had a single perianal fistula tract and had failed previous treatment or had documented medication intolerance to biologic or conventional CD therapy. All enrolled subjects underwent surgical fistula optimization and adipose tissue biopsy collection (to manufacture AVB-114) followed by 1:1 randomization to either standard of care (repeat fistula optimization including seton replacement) or AVB-114 implantation. The primary end point was combined fistula remission at 36 weeks, defined as closure of the external opening, no drainage of fluid despite gentle finger compression, and no collections >2 cm in at least 2 of the 3 dimensions on MRI. RESULTS: Subjects at 14 US sites were equally randomized to SoC (N = 24) or AVB-114 (N = 24). Week 36 combined remission was 8.3% and 45.8% for subjects randomized to SoC and AVB-114, respectively (38% difference, 95% CI 11%-60%; P = 0.0078). At week 36, MRI revealed no subjects with collections >2 cm, radiological improvement (≥50% decrease in the Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease (MAGNIFI-CD) score from baseline) in 1 SoC subject and 3 AVB-114 subjects, and radiological healing (complete resolution of T2-weighted hyperintensity in fistula tract) in 2 SoC subjects and 5 AVB-114 subjects. Through week 36, there were 40 and 56 treatment emergent adverse events for SoC and AVB-114, respectively. There were no serious treatment emergent adverse events in the AVB-114 group through week 36. DISCUSSION: A significantly higher proportion of patients treated with AVB-114 achieved combined remission vs SoC, and the treatment was well tolerated. These data support the safety and efficacy of AVB-114 in persistent Crohn's perianal fistulas.
引用
- Schwartz DA, Dozois E, Ehman E, et al. AVB-114 Demonstrates Clinical Benefit in Persistent Crohn's Perianal Fistulas: Randomized Cohort Results From the Multicenter STOMP2 Trial. Am J Gastroenterol. 2026. PMID: 41879234. doi:10.14309/ajg.0000000000004005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。